Weld Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Weld Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,108	Closed	-$442K	–	580
2020 Q1	$442K	Buy	+5,108	New	+$500K	0.23%	160
2019 Q4	–	Sell	-4,733	Closed	-$426K	–	819
2019 Q3	$426K	Buy	+4,733	New	+$442K	0.08%	441
2019 Q2	–	Sell	-7,204	Closed	-$635K	–	875
2019 Q1	$635K	Sell	7,204 -1,362	-16%	-$114K	0.12%	324
2018 Q4	$612K	Buy	+8,566	New	+$821K	0.14%	284

Other funds holding NBIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Weld Capital Management's NBIX Position: Q2 2020 in Review

Weld Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2020, closing a stake of 5,108 shares — an estimated $442K sold.

Weld Capital Management first reported a position in NBIX in Q4 2018 and held it in 4 quarters. The position peaked at $635K in Q1 2019. 418 funds tracked by Wall St. Rank hold NBIX as of Q2 2020.

Weld Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2020 after selling out during the quarter.
Weld Capital Management sold 5,108 Neurocrine Biosciences shares in Q2 2020, an estimated $442K.
Weld Capital Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 4 quarters.
Weld Capital Management's Neurocrine Biosciences position peaked at $635K in Q1 2019.
418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2020.

Based on Weld Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.